Qualifications

  • LL.B. (Hons), National University of Singapore
  • Admitted to the Singapore Bar (1992)

Tony is the Managing Director of our Intellectual Property department, and a Director in our Dispute Resolution department. He also heads our Healthcare & Life Sciences Practice. Tony is currently representing leading biotech and pharmaceutical companies such as Sanofi-Aventis, Novartis, and Becton Dickinson; government statutory boards such as Sentosa Development Corporation, and Health Promotion Board; as well as listed companies such as PT Bayan Resources Tbk and Manhattan Resources Ltd.

Tony is a litigator with an active court practice as an advocate. He has acted as lead counsel in many complex matters, including numerous patent infringement cases. He is experienced in intellectual property litigation and enforcement including patent, trade mark, and copyright litigation. His civil and commercial litigation practice includes banking litigation and contract disputes.

Tony was appointed by the Intellectual Property Office of Singapore (IPOS) as an IP Adjudicator for a two-year term from April 2019. He is also the President of the International Association for the Protection of Intellectual Property (AIPPI) – Singapore Group, a member of the Law Society’s Inquiry Committee and Disciplinary Tribunal, and a member of the Examination Board at IPOS for registered patent agents.

He also co-authored the Singapore chapter of Global Pharmacovigilance Laws & Regulations: The Essential Reference, which has been described as a “groundbreaking book” and a “landmark guide” published by the US based Food and Drug Law Institute. Tony also co-wrote the article “Legislating medical devices in Singapore” in Financier Worldwide: Biotechnology & Life Sciences e-Book 2010.

Under his guidance and leadership, Drew & Napier clinched double wins at the 2018 Asia IP Awards, winning both the Singapore Trade Mark Firm of the Year and the Singapore Patent Firm accolades.

Tony has been involved in many high profile matters. Here are just a few recent cases:


  1. Representing Becton Dickinson Medical (S) Pte Ltd ("Becton Dickinson"), a global leading medical technology company, in an on-going patent infringement suit commenced by B. Braun Melsungen AG ("B. Braun") in HC/Suit 655/2018, in relation to medical catheters. Becton Dickinson has counterclaimed for, inter alia, a declaration of non-infringement and a declaration that B. Braun’s patent is invalid. This suit is part of the ongoing litigation and contentious proceedings in various jurisdictions between Becton Dickinson and B. Braun.

  2. Representing IIa Technologies Pte Ltd., an industry leader in state-of-the-art lab grown diamond technology, in a patent infringement suit commenced by Element Six Technologies Ltd, a subsidiary of the De Beers Group, in HC/Suit No. 26/2016.

  3. Representing TWG Tea Company Pte Ltd (“TWG Tea”), a subsidiary of public listed OSIM International Ltd, in HC/S 799/2017. TWG Tea is a home-grown brand famous for its luxury tea boutiques and salons. The action was started TWG Tea against a former office holder and shareholder of TWG Tea (“Defendant”) for the return of TWG Tea domain name. Also acted for TWG Tea and two of its office holders in the counterclaim brought by the Defendant for malicious falsehood, unjust enrichment and conspiracy.

  4. Acted as lead counsel representing Sentosa Development Corporation, a statutory board, in Suit 1084/2014, in an action involving the use of the well-known SENTOSA trade mark. This action also involves Rule 13 of the Trade Mark Rules, governing inter alia the registration of a mark which bears the name or initials of any government body or statutory board.

  5. Acted as lead counsel representing Novartis AG and its subsidiary Novartis (Singapore) Pte Ltd in 2 ongoing actions, Suit 1298/2014 and Suit 44/2015, under Section 12A of the Medicines Act, involving patents in relation to the drug with the active ingredient imatinib and marketed under the brand name GLIVEC®. Separately, Tony also successfully represented Novartis AG and Novartis (Singapore) Pte Ltd to amend the patent in litigation in the Singapore High Court decision of Novartis AG and Novartis (Singapore) Pte Ltd v Ranbaxy (Malaysia) Sdn Bhd [2012] SGHC 253

Chambers Asia-Pacific

Intellectual Property 2019 – Band 1

Band 2 (2009 to 2018)

Clients say that Tony is "a seasoned patent litigator".

“He quickly understands complex IP issues and is able to convey them in a way that is easy to understand,” adding: “He understands the client's needs and delivers results that meet the company's strategy and goals. He is also very creative and thinks outside the box.”

He is extremely hands-on, clear in his thinking, has foresight and draws a lot of perspective from his past experience to evaluate the next steps,"

"...with Tony we are well informed, and he always walks in with a sound plan which makes it easy to make an informed decision.”

"[Tony] leverages on his strong healthcare and life sciences sector expertise and regularly acts for major pharmaceutical clients in notable patent infringement disputes."

"A highly reputed litigator in the IP practice who is described as both "hugely enthusiastic" and "very commercial.""

“A very confident individual who always stays on top of the situation."

Managing Intellectual Property
Voted an IP Star 2018 – Patent litigation, Patent prosecution, Trade mark litigation, Trade mark prosecution

“Tony is responsive, quick thinking and highly practical in his advice.”

“First class service and quality work”

Tony [Yeo] is charming, knowledgeable, and has a knack of explaining things simply and in the context of the overall strategy. He is an effective litigator and is incisive in cross-examinations."

The Asia Pacific Legal 500
Intellectual Property 2019 – Leading individual for 9 consecutive years
Dispute Resolution 2018 – Recommended lawyer

Sources say that Tony is “a fantastic strategist and a great litigator”

“Diligent, sound in judgment and pragmatic in approach”

“One of the foremost lawyers in Drew & Napier’s excellent litigation practice with in-depth knowledge of IP-related issues”

Asialaw Leading Lawyers
Intellectual Property and Dispute Resolution 2018 – Market-Leading Lawyer for 2 consecutive years

Client feedback (2017): “Market-leading lawyer Tony Yeo’s “strategic thinking, honesty and timely responsiveness”… (is) prized by clients.”

Who’s Who Legal
Life Sciences 2019 – Leading Lawyer for 9 consecutive years

“Tony Yeo is recommended across our life sciences chapters for his wide-ranging expertise in the area.”

Patents 2018 – Leading Lawyer for 5 consecutive years

Trademarks 2018 – Leading Lawyer for 2 consecutive years

Clients say Tony is a “formidable litigator” who is “extremely knowledgeable in IP matters”. He impresses with his “ability to balance commercial considerations with effective legal strategies”.

Benchmark Litigation Asia-Pacific 2019 edition
Identified as a Dispute Resolution Star in Intellectual Property

Clients say: “Tony is responsive, commercially aware and a skilled advocate”

World Trade Mark Review 1000
Enforcement and Litigation 2019 – Recommended individual for 2 consecutive years 

Sources commend Tony’s “efficient delivery” of “well-informed” strategies.

IAM Patent 1000
Ranked gold band in litigation in 2019

“Managing director of intellectual property Tony Yeo is most at home when resolving intricate patent disputes on behalf of major clients in the healthcare and life sciences arenas. Renowned for his silver-tongued advocacy, Yeo is a master of cross-border and technically advanced patent infringement suits.”

“Famed for its strength in disputes, the firm boasts no shortage of star litigators – and Tony Yeo stands out among them. A courtroom sharpshooter with over 25 years’ experience in patent litigation…”

Life sciences captain Tony Yeo “keeps competitors on their toes” in hotly contested disputes between big pharma combatants.

“Clients adore the highly intelligent Tony Yeo; his facility for grasping the technicalities of a case means that he always quickly addresses the real problem.”

[Tony Yeo] is “bright and extremely easy to work with. He has a good instinct for the right answer and always provides sensible and pragmatic advice”.

World IP Review 
Identified as a leading practitioner in IP in 2017

Asia IP Experts 2018
Listed as a leading individual for 3 consecutive years in IP Enforcement, Patents, and Litigation

Listed as a leading individual in Pharma & Biotech for 6 consecutive years

ILO Client Choice Awards
Winner of the Singapore Healthcare & Life Sciences Award 2013

Asian Legal Business
Ranked among other lawyers in ALB’s Hot 100

  • IP Adjudicator at the Intellectual Property Office of Singapore (IPOS) from April 2019 for a two-year term
  • President, International Association for the Protection of Intellectual Property (AIPPI) Singapore Group
  • Honorary legal counsel, Orchard Road Business Association (ORBA)
  • Honorary legal counsel, Singapore Advertisers Association
  • Member, Singapore Patent Agents Examination Board at the IPOS
  • Member, Accounting and Corporate Regulatory Authority (ACRA) Disciplinary Committee
  • Member, Supreme Court Pleadings Precedent Selection Committee - Intellectual Property
  • Member, Law Society’s Inquiry Panel and Disciplinary Tribunal
  • Member, Asian Patent Attorneys Association
  • Member, International Trademark Association
  • “Life Sciences Jurisdictional Guide to Singapore” in Practical Law Company Multi-Jurisdictional Guide 2013, 2014, 2015, 2016 and 2017
  • The Singapore chapter of Life Sciences, Getting the Deal Through, 2014, 2015, 2016 and 2017
  • “Developments in Singapore’s Healthcare Regulatory Landscape” in Asian Legal Business November 2013
  • The Singapore chapter of “Global Pharmacovigilance Laws & Regulations: The Essential Reference” published by the Food & Drug Law Institute, which has been described as a “groundbreaking book” and a “landmark guide”
  • “Legislating medical devices in Singapore” in Financier Worldwide: Biotechnology & Life Sciences e-Book 2010